AKT1 and central nervous system cancer: Thus, it is concluded that ARHGEF9 is a glioma suppressor gene that acts through the PI3K/AKT/mTOR pathway, which reveals part of the mechanism between peptides and gliomas and provides a new potential therapeutic target and a prognostic biomarker for patients.